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Abstract 
4-methylamphetamine (4-MA) has recently emerged as a designer drug of abuse 
in Europe and it is consumed always with amphetamine. There have been reported 
some deaths and non-fatal intoxications related to 4-MA. We investigated the changes 
in locomotor activity and body temperature after 4-MA administration to male Sprague-
Dawley rats. Our experiments were carried out at a normal or high ambient 
temperature. 4-MA (2.5 - 10 mg/Kg, given subcutaneously) increased, in a dose-
dependent manner, the horizontal locomotor activity that was significantly reduced by 
ketanserin, p-cholorophenylalanine (pCPA) or haloperidol. In addition, we have studied 
the effect of 4-MA on core body temperature by means of an implanted electronic 
thermograph, enabling continuous measurement of body temperature. We observed a 
dose-dependent hypothermic response to 4-MA that reached a maximum 45 min after 
a single injection. We also evidenced slight tachyphylaxis to the hypothermic effect 
when 4-MA was administered four times in a 2 h interval. The pre-treatment of animals 
with pCPA or pindolol, but not with ketanserin, fully abolished the hypothermic effect of 
4-MA. With all that, we conclude that hypothermia induced by 4-MA is due to the 
release of 5-HT which activates postsynaptic 5-HT1A receptors. 
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1. Introduction 
4-Methyl-amphetamine (1-(4-methylphenyl)-propane-2-amine; 4-MA) belongs to 
the group of new psychoactive substances of abuse named and sold as “research 
chemicals” over the Internet. It seems that 4-MA could be produced accidentally as a 
result of the use of uncontrolled precursors in the illegal production of amphetamine. 
The available evidence suggests that, in most cases, 4-MA is sold as amphetamine, 
and so users are usually unaware of this. When studied as an appetite suppressant 
agent in the 1950s, 4-MA underwent human clinical trials and the only available study 
was published in 1952 [1]. However, 4-MA was never made commercially available as 
a clinically useful drug. 
 
In 2011, 4-MA was found, for the first time, in a seized powder mixture with 
amphetamine and caffeine in Germany (EMCDDA1, 2012). Belgium reported six deaths 
where 4-MA was detected in either post-mortem blood, urine or tissues. In all cases, 
amphetamine was also present. The concentration of amphetamine in those samples 
was not very high and, apparently, the cause of death was related to the combined 
intake of 4-MA and amphetamine. Thereafter, there have been sixteen more deaths 
and nine non-fatal intoxications related to 4-MA reported in Europe. In 2013, the 
European Union Council decided an EU-wide control. 
 
The reported human toxicity is most likely the result of the combined dopaminergic 
activity of amphetamine and the serotonergic activity of 4-MA [2]. In this regard, it was 
described a massive adrenergic overstimulation just after inhaling material, which had 
been purchased in the belief that it was amphetamine but also contained 4-MA and 
dimethyl-amphetamine [3]. Only in one case, a patient with forensic evidence of 4-MA, 
developed extreme hyperthermia and died after cardiac arrest, although he had 
consumed ketamine, cocaine and other amphetamines 24 h before (EMCDDA-Europol 
report 2012). 
  
There are very few published studies on the pharmacology of 4-MA in laboratory 
animals [4,5]. It has been speculated that, compared to amphetamine, the most 
pronounced serotonergic action of 4-MA could diminish the psychoactive effects of 
amphetamine leading to the consumption of repeated and higher doses of 
contaminated amphetamine [2]. 
 
                                                          
1
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Serotonin (5-HT) in the hypothalamus is involved in the regulation of body 
temperature [6]. Stimulation of 5-HT2 receptors in hypothalamic neurons mediates 
hyperthermic effects, whereas stimulation of the 5-HT1A receptors in these neurons 
inhibit the endogenous release of hypothalamic 5-HT and leads to hypothermic effects 
[7,8]. It is well known that the effects of amphetamine on body temperature are 
biphasic and, although low doses induce decreases in body temperature, higher doses 
produce vigorous thermogenesis [9,10]. To our knowledge, there is no study about the 
effects of 4-MA on body temperature. 
 
Because the main problem associated to 4-MA exposure is the acute toxicity of 
this drug, which seems to be linked to hyperthermia, the aim of the present study was 
to characterize 4-MA as regards to its ability to induce a psychostimulant effect and, 
what is more important, to alter body temperature in rats. We focused our attention on 
5-HT system. This represents a first approach to characterize the pharmacology of 4-
MA in rats and hypothesizes the translation of its effects to human abusers. 
 
2. Materials and methods 
2.1. Animals and treatments 
Male Sprague-Dawley rats (125 – 175 g) (Janvier, Lé Genest, France) were used. 
The animals were housed in a regulated ambient temperature with a 12 h light/dark 
cycle (lights on at 08:00 h) with free access to food and water. Saline and 4-MA were 
administered subcutaneously. Ketanserin, haloperidol and pindolol were dissolved in 
saline and administered intraperitoneally 20 min before saline or 4-MA. Treatment with 
p-chlorophenylalanine (pCPA) was carried out at a dose of 300 mg/Kg (i.p.) given daily, 
over the course of three days. Eighteen hours after the last dose of pCPA, the animals 
received saline or 4-MA. Experimental protocols for the use of animals in this study 
were approved by the Animal Ethics Committee of the University of Barcelona under 
the supervision of the Autonomous Government of Catalonia, and following the 
guidelines of the European Communities Council (86/609/EEC).  
 
2.2. Synthesis of 4-MA  
We synthesized 4-MA following the procedure previously described [11] with some 
modifications. Briefly, 4-methylphenyl-2-nitropropene precursor was obtained by the 
classical Knoevenagel condensation between p-tolualdehyde and nitroethane in acetic 
acid/ammonium acetate. The mixture was heated at 50 - 60 ºC for 2 h and the reaction 
was stopped with cold water. The yellow solid was filtered and recrystallized from 
ethanol/hexane (1:1). The 4-methylphenyl-2-nitropropene was dissolved in 
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tetrahydrofuran (THF) and lithium aluminium hydride solution (1M) in THF was added 
drop wise. The mixture was allowed to stir overnight at room temperature. Excess 
hydride was decomposed by the cautious addition of H2SO4 (8%). Diethylether was 
added and the aqueous layer was extracted and cleaned with potassium sodium 
tartrate. The aqueous layer was made alkaline using NaOH (5%) and the amine was 
extracted with dichloromethane. Finally, the free base was converted to the 
hydrochloride salt using a solution of hydrogen chloride (2M) in diethylether. The 
identification of 4-MA was assessed by 1H NMR) (d6-DMSO) yielding the following 
results: δ 8.32 (s, 3H); 7.13 (d, 2H) J=8.4 Hz; 7.10 (d, 2H) J=8.4 Hz; 3.32 (m, 1H); 2.99 
(dd, 1H) J=13.4, 5.2 Hz; 2.59 (dd, 1H) J=13.4, 9.2 Hz; 2.27 (s, 1H); 1.08 (d, 3H) J=6.4 
Hz. Chemical purity of the obtained compound was also assessed by melting point 
determination, thin layer chromatography and mass spectrometry. All analytical data 
were consistent with the assigned structure with over 98% purity for the 4-MA. 
Isoflurane was from Lab Dr. Esteve (Barcelona, Spain). All other drugs and 
reagents were obtained from Sigma-Aldrich (St. Louis, MO,USA). 
2.3. Spontaneous locomotor activity  
Prior to experimentation, all rats received two habituation sessions of manipulation 
(48 and 24 h before testing) whose purpose was to reduce the novelty and stress 
associated with handling and injection. During these sessions, animals were placed in 
a Plexiglas cage. This cage constituted the activity box that was later placed inside a 
frame system of two sets of 16 infrared photocells (LE8811, PANLAB, SL, Barcelona, 
Spain) mounted according to the x, y axis coordinates and 1.5 cm and 7.5 cm above 
the wire mesh floor. Occlusions of the photo beams were recorded and sent to a 
computerized system (SedaCom32, PANLAB, SL, Barcelona, Spain). The interruption 
counts of the lower level, over a 10 min-slot, were used as a measure of horizontal 
locomotor activity. Similarly, interruption counts of the upper level were used as a 
measure of rearing. On the day of testing, the animals were placed in the activity box 
and received the drug treatment 30 min after. Results are expressed as AUC (area 
under the curve), which was measured as the total changes from baseline at each 
recording interval over 150 min. 
 
2.4. Surgical procedures and continuous acquisition of body temperature 
The animals were allowed 1 week after arrival to acclimatize before surgery. 
Subsequently, they had implanted an electronic thermograph (Thermo Tracker, 
Barcelona, Spain), enabling continuous measurement of core body temperature. The 
implant was placed in the abdominal cavity as follows: the rats were anesthetized with 
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isoflurane, the abdomen was opened by making a 2-cm midline incision and the device 
was placed in the abdominal cavity, along the sagittal plane. The abdominal and the 
skin wound were then closed with absorbable suture material. After surgery, animals 
were individually housed, received analgesic therapy and were allowed to recover for 7 
days before saline or 4-MA administration. The device registered the core temperature 
every 5 min and the values were downloaded to a computer after removal of the 
device, once the animals had been sacrificed, using the interface and software 
provided by the manufacturer. Data were acquired from 2 h prior to until 12 h after drug 
administration. 
 
2.5. Statistical analyses 
Data were analysed using one way analysis of variance (ANOVA) followed by 
Tukey‟s post-hoc test for multiple comparisons, or Student-t test when appropriate, 
using GraphPad Instat (GraphPad, San Diego, CA). The difference between treatments 
was considered statistically significant at p < 0.05. All results were expressed as mean 
± S.E.M. 
 
3. Results 
 
3.1. Effect of 4-MA on spontaneous locomotor activity 
An overall ANOVA demonstrated an extremely significant effect of 4-MA treatment 
(2.5 -10 mg/Kg) in the increase of horizontal locomotor activity in rats (F3,14 = 16.872, p 
< 0.001). This increase was dose-dependent (Fig. 1). 
Except for the lowest dose, the duration of the hyperlocomotive effect was of 120 
min. In addition to our analysis of locomotor activity, we simultaneously recorded the 
number of rearings as a measure to determine the habituation of animals to the novel 
environment. The animals treated with different doses of 4-MA showed no difference 
with saline group in this behaviour (F3,14 = 2.233, n.s.).  
In a separate group of experiments, we monitored the locomotor response to 4-MA 
(2.5mg/kg), at normal (21 ± 1 ºC) and high (26 ± 1 ºC) ambient temperature. No 
differences were found (AUC values: 50850  1420, at normal and 46411  1420 at 
high ambient temperature). 
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3.1.1. Involvement of 5-HT and DA in the psychostimulant effect of 4-MA 
A series of experiments with animals pre-treated with different compounds were 
carried out to better understand the mechanism responsible of the increase of 
locomotor activity induced by 4-MA (administered at a dose of 2.5 mg/Kg). To prove 
the involvement of 5-HT we pre-treated animals with a dose of ketanserin (1 mg/Kg), 
an antagonist of 5-HT2A/2C receptors, that did not affect the basal locomotor activity. 
This compound inhibited partially the effect of 4-MA. Additionally, the pre-treatment of 
animals with pCPA, an inhibitor of 5-HT synthesis (3 x 300 mg/kg), significantly 
reduced the effect of 4-MA. Furthermore, to prove the involvement of dopamine in the 
increase of locomotor activity induced by 4-MA we pre-treated animals with the 
maximum dose of haloperidol (0.1 mg/Kg), an antagonist of dopamine receptors, which 
did not affect the locomotor activity. This compound inhibited partially the effect of 4-
MA (Fig. 2). 
 
3.2. Effect of 4-MA on body temperature 
3.2.1. Effect of a single dose of 4-MA at normal and high ambient temperature 
In experiments performed at a normal (21 ± 1 ºC) ambient temperature, we 
observed a strong but transient dose-dependent hypothermic response that persisted 
until 90-100 min after the administration of 4-MA. When the curve profile analysis was 
carried out, it showed a maximum drop in body temperature between 40 and 45 min 
after drug administration (Fig. 3). What is more, saline-treated rats exhibited an overall 
non-significant (p = 0.085) increase in temperature after 4-MA administration, probably 
due to the stress induced by the injection.  
 
It has been argued that amphetamines‟ toxicity may be potentiated by the 
overheated environments as they exacerbate one of the most toxic effects of the drug, 
the impairment of thermoregulation [12]. To this end, we have studied the effect of 4-
MA in a high temperature environment (26 ± 1 ºC). When experiments were performed 
at this temperature, the hypothermic response induced by 4-MA also took place (F2,16 = 
8.566, p < 0.01), (saline: 37.73 ± 0.21, n = 5; 4-MA 2.5 mg/Kg: 36.25 ± 0.29, n = 6, p < 
0.05 vs saline; 4-MA 5 mg/Kg: 35.79 ± 0.43, n = 6, p< 0.01, vs saline). The lowest body 
temperature was observed at 90-100 min after drug administration. Notice that the 
maximum drop in body temperature appeared later than that observed at 21 ºC. 
 
3.2.2. Effect of repeated doses of 4-MA . 
It is known that some tolerance or tachyphylaxis to the hyperthermic effect of 
certain psychostimulant drugs [13] can exist. We administered 4-MA at three different 
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doses (2.5, 5 and 7.5 mg/Kg) four times in a 2 h interval in a normal ambient 
temperature. As can be seen in Table 1, all administered doses induced hypothermia. 
Tachyphylaxis to this effect was only detected after the fourth administration because 
the maximum of hypothermia (at both fourth doses of 5 and 7.5 mg/Kg) differed from 
the first one (p < 0.05). 
 
3.2.3. Effect of blockade of 5-HT synthesis 
As previously stated, we investigated the role of endogenous 5-HT on the effect of 
4-MA on body temperature. pCPA was administered in the same schedule previously 
described for locomotor activity experiments. The obtained results (saline: 37.75 ± 0.24 
ºC, n = 5; 4-MA 2.5 mg/Kg: 35.96 ± 0.37 ºC, n = 5, p < 0.05, vs saline; pCPA: 36.90 ± 
0.49 ºC, n = 5; pCPA + 4-MA 2.5 mg/Kg: 37.18 ± 0.30 ºC, n = 5), demonstrated that the 
blockade of 5-HT synthesis fully abolished the hypothermic effect of 4-MA. 
 
3.2.4. Effect of 5-HT1A/5-HT2 receptor blockade 
Animals were pre-treated with pindolol (2 mg/Kg) before 4-MA (2.5 mg/Kg). 
Pindolol fully abolished the hypothermic effect of 4-MA. 
Obtained results were as follows: saline: 37.41 ± 0.26 ºC, n = 5; 4-MA 2.5 mg/Kg: 
35.79 ± 0.46 ºC, n = 5, p < 0.05, vs saline; pindolol: 37.70 ± 0.23 ºC, n = 4; pindolol + 
4-MA 2.5 mg/Kg: 37.13 ± 0.56 ºC, n = 4). On the contrary, pre-treatment of animals 
with ketanserin (1 mg/Kg) did not inhibit the hypothermia induced by 4-MA (saline: 
37.76 ± 0.20, n = 5; 4-MA 2.5 mg/Kg: 35.95 ± 0.31, n = 5, p < 0.05, vs saline; 
ketanserin: 36.96 ± 0.29, n = 3; ketanserin + 4-MA 2.5 mg/Kg: 35.96 ± 0.37, n = 5, p < 
0.05, vs saline). Consequently, the blockade of 5-HT1A (not 5-HT2) receptors abolished 
the hypothermic effect of 4-MA. 
 
4. Discussion 
Originally developed as an appetite suppressant, 4-MA has recently raised again 
as a new psychoactive substance in Europe, and it can be found as a drug of abuse, 
always mixed with amphetamine [14]. 4-MA can be produced at a relatively low cost 
and the precursors known to be used for its manufacture are not under control and 
appear to be commercially available. It is unclear to what extent 4-MA is 
advertised/sold via the Internet. The observed toxicity in humans is most likely the 
result of the combined dopaminergic activity of amphetamine and the serotonergic 
activity of 4-MA. Also, slow metabolism of 4-MA and its MAO-inhibiting properties can 
also contribute to the toxicity of 4-MA [14]. 
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There are very few published studies on the pharmacology of 4-MA. This 
compound is equipotent as a releaser of dopamine, norepinephrine and 5-HT [4], It 
also shows low affinity for 5-HT2 receptors [15]. However, with respect to 5-HT release, 
4-MA was significantly more potent compared to amphetamine [4].   
Studies of the behavioural actions of amphetamines commonly focus on 
locomotion. Wellman et al. compared the psychostimulant effect of three amphetamine 
analogues, including 4-MA [5]. They concluded that 4-MA had a very low effect on 
locomotion that is attributed to a high activity at 5-HT transporter. In that study, the 
range of doses used was up to 2.4 mg/Kg and locomotion was registered over three 15 
min periods (15, 30 and 45 min after injection). 
In the present study, the hyperlocomotion induced by 4-MA was dose-dependent 
and already present at the dose of 2.5 mg/Kg. This effect was not affected by 
increasing the ambient temperature. There is limited information available from user 
reports or Internet discussion forums about 4-MA dosage. The only information is from 
an abuser that self-reported use of 4-MA by oral (160 mg) and intramuscular (80–120 
mg) route (EMCDDA, 2012). The human equivalent doses of the range used (2.5 – 10 
mg/Kg) in the present study, although given subcutaneously, are 30 – 120 mg [16], 
which are in agreement with those reported as psychostimulants. 
It is known that amphetamine derivatives, like MDMA, produce an increase in the 
dopamine release by activating 5-HT2 receptors, which may also contribute to the 
hyperlocomotion [17]. In present experiments, when animals were pre-treated with 
ketanserin or haloperidol (at doses that did not affect basal locomotor activity), the 
hyperlocomotion of 4-MA was partially inhibited, suggesting both 5-HT and dopamine 
take part in this effect. According to previously published studies [15] ruling out a direct 
activation of 5-HT2 receptors by 4-MA, we hypothesize that this drug promotes the 
release of  5-HT, which can activate 5-HT2 receptors, inducing an increase of synaptic 
dopamine concentration that finally activates dopamine receptors and contributes to 
hyperlocomotion. The inhibition after pCPA treatment demonstrates the role of 
endogenous 5-HT in the hyperlocomotion induced by 4-MA. Furthermore, 4-MA-treated 
rats did not experience the environment as a novel one (absence of significant 
difference in rearings from saline-treated animals), 
The main problem associated to 4-MA exposure is the acute toxicity of this drug, 
which seems to be linked to hyperthermia. For this reason, we focused our attention on 
the effects of 4-MA on body temperature. We have studied it after an acute dose of 4-
MA but, in the effort to mimic recreational use, we also considered appropriate to 
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simulate the widespread practices of “boosting or redosing” (taking supplemental doses 
over time in order to maintain the drug effect, hence becoming dependent to achieve 
the „high‟ effect). For this reason, we chose to administer multiple doses of 4-MA during 
a daily session, with an interval of 2 h between doses [18]. 
In our experiments, 4-MA induced a consistent hypothermic response that 
persisted for 90-100 min, in all the doses assayed. Green et al. studied the effect of 
MDMA on body temperature and found that its administration to rats produces 
hyperthermia if animals are housed in normal or warm ambient room temperature 
conditions ( 20°C), but hypothermia when in cool conditions ( 17°C) [19]. Perhaps 
the difference between both drugs is that the potency and selectivity of 4-MA as 
serotonin releaser is higher than other amphetamine derivatives [4]. A slight 
tachyphylaxis to this effect was found because after a repeated administration 
schedule, the maximum of hypothermia after the fourth administration significantly 
differed from the first one. 
It has been described that local perfusion of the hypothalamus with 5-
hydroxytryptophan (a 5-HT precursor) or fluoxetine (a 5-HT reuptake inhibitor) 
increases body temperature by increasing extracellular concentrations of 5-HT, which 
activate central 5-HT2A receptors [20,21], although activation of these receptors in the 
peripheral system leads to hypothermia [22]. Additionally, an activation of 5-HT1A 
receptors in the hypothalamus leads to hypothermia [23]. 
In our experiments, 4-MA induced hypothermia was not abolished by a 5-HT2A/2C 
receptor antagonist. Additionally, results from pindolol and pCPA-treated animals in 
which the hypothermic effect of 4-MA was significantly reduced, lead us to conclude 
that hypothermia induced by 4-MA can be the consequence of 5-HT release that 
activates postsynaptic 5-HT1A receptors [23]. 
 
5. Conclusions 
To sum up, we have shown that 4-MA, at doses that imitate human recreational 
use, induces an increase on the horizontal locomotor activity in rats, involving both 5-
HT and dopamine. Moreover, at the same doses, 4-MA induces dose-dependent 
hypothermia by an activation of postsynaptic 5-HT1A receptors. These results make it 
very unlikely that the only event of hyperthermia described in humans could be due to a 
direct effect of 4-MA. Overall, this study states as the first approach to characterize the 
pharmacology of 4-MA in rats and contributes to our knowledge of this new drug of 
abuse. 
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Legends of figures 
 
Fig. 1. Effect of a single subcutaneous administration of 4-MA (2.5, 5 or 10 mg/Kg) and 
saline. For locomotor activity, the interruption counts in the lower frame of the 
apparatus were registered, displayed in a 10 min-slot and monitored for 150 min. Data 
are expressed as the mean ± SEM of values from 4 animals. *p < 0.05, ** p < 0.01 and 
***p < 0.001 vs saline. 
 
Fig. 2.  Effect of ketanserin (Ket) (1 mg/Kg), haloperidol (Hal) (0.1 mg/Kg) and pCPA (3 
x 300 mg/kg) on the increase of locomotor activity induced by 4-MA (2.5 mg/Kg). Data 
(AUC, Area under the Curve) are expressed as the mean ± SEM of values from 5 
animals. *p < 0.05 and ** p < 0.01 vs 4-MA. 
 
 
Fig 3. Effect of 4-MA on core body temperature. Rats (n=5 per group) were treated 
with saline (1ml/Kg, s.c.) or 4-MA (1, 2.5, 5 or 10 mg/Kg, s.c.) and core body 
temperature was recorded using an electronic implant at 5 min-intervals for 12 h. 
Results are presented as group means. All SEM values are omitted for the sake of 
clarity. Injection time is indicated by an arrow. 
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Table 1. Effect of repeated doses, at 2 h interval, of 4-MA on body temperature. Results denote the maximum of hypothermia and the time after each 
injection in which this maximum is achieved. Results are expressed as mean ± S.E.M. from four animals. * p < 0.05 versus the first dose. 
 
 
 
Dose 1 Dose 2 Dose 3 Dose 4 
Drug 
Temp 
(°C) 
Time 
(min) 
Temp 
(°C) 
Time 
(min) 
Temp 
(°C) 
Time 
(min) 
Temp 
(°C) 
Time 
(min) 
Saline 37.87 ± 0.26 ---- 37.71 ± 0.19 ---- 37.44 ± 0.17 ---- 37.21 ± 0.16 ---- 
4-MA 
(2.5 mg/Kg) 
36.09 ± 0.27 45 35.06 ± 0.28 40 35.31 ± 0.18 45 36.31 ± 0.80 40 
4-MA 
(5 mg/Kg) 
34.31 ± 0.31 50 34.63 ± 0.29 60 35.44 ± 0.38 50 35.97 ± 0.40* 45 
4-MA 
(7.5 mg/Kg) 
33.54 ± 0.29 75 33.88 ± 0.82 60 34.00 ± 0.63 55 34.63 ± 0.27* 65 
Table 1
